Target screening method and device for predicting occurrence of human complex disease phenotypes and medium

Through genome-wide association research and single-cell transcriptomics, targets with good colocal properties were screened out, which solved the problem of predicting phenotypes of human complex diseases, achieved efficient and accurate target screening and intervention, and improved disease prediction and the accuracy of treatment.

CN119007803AActive Publication Date: 2024-11-22INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411251941.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-06
Publication Date
2024-11-22
Estimated Expiration
2044-09-06

AI Technical Summary

Technical Problem

The prior art is difficult to accurately predict the occurrence of complex human disease phenotypes, leading to the difficulties of clinical intervention and prevention of elderly diseases.

Method used

By obtaining genotype-phenotype association data, conducting genome-wide association studies and quantitative trait loci localization, screening out monocyte targets with good colocal properties, combining single-cell transcriptomics to accurately locate easy-to-localize the loci Sensory genes and molecular mechanisms to achieve target screening.

Benefits of technology

It improves the performance, efficiency and accuracy of target screening, and can dig out massive genetic evidence in a short period of time, accurately predict targets of complex diseases, break through the limitations of traditional target discovery models, and improve the success rate of intervention and treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119007803A_ABST
    Figure CN119007803A_ABST
Patent Text Reader

Abstract

The invention discloses a target screening method and device for predicting occurrence of human complex disease phenotypes and a medium, and relates to the field of target screening, the method comprises the following steps: screening and grouping GWAS data based on a preset window to obtain a first leadsnp set, the first leadsnp in each subset being snp with the minimum p value in the corresponding preset window range in the GWAS data; matching, screening and grouping the QTL data based on a preset window and the first leadsnp set to obtain a second leadsnp set; and performing co-localization analysis based on the second leadsnp set, the GWAS data and the QTL data, performing GWAS-QTL correspondence calculation, determining a target p value and a target correspondence score, and screening a target leadsnp from the second leadsnp set as a target point based on the target p value and the target correspondence score. According to the invention, the target spot is rapidly and accurately screened out, and the performance, efficiency and accuracy of co-localization screening are improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of target screening, and in particular to a target screening method, device and medium for predicting the occurrence of complex human disease phenotypes. Background Art

[0002] The inherent stochasticity of biochemical reactions leads to a wide distribution of gene expression in cell populations, even in seemingly homogeneous cell populations. This phenomenon is called "gene expression noise" and is widely observed in both prokaryotic and eukaryotic systems. Many studies have shown that noise is involved in a variety of important biological and pathological processes. For example, changes in transcriptional variability of pluripotent cells have been observed at different stages of embryonic development. In addition, transcriptional variability increases with age, and the disruption of noise control may lead to abnormal immune responses and confusion in cell recognition, inducing a series of aging-related diseases.

[0003] It is not clear at present which targets transcriptional noise regulates to affect the occurrence of complex human disease phenotypes. In addition, the aging of the body will lead to an increasing incidence of chronic diseases and the phenomenon of multiple diseases. Chronic diseases are mostly degenerative changes caused by the combined effects of internal and external factors during the aging process of the body, and there are differences in tissues or cells. How to accurately predict the occurrence of these complex disease phenotypes so that clinicians can intervene in time and prevent the occurrence and development of elderly diseases is a difficult problem that urgently needs to be solved. Summary of the invention

[0004] The purpose of this application is to provide a target screening method, equipment and medium for predicting the occurrence of complex human disease phenotypes, quickly and accurately screen out target targets, and improve the performance, efficiency and accuracy of co-localization screening.

[0005] To achieve the above objectives, this application provides the following solutions:

[0006] In a first aspect, the present application provides a target screening method for predicting the occurrence of complex human disease phenotypes, comprising:

[0007] Acquire genotype-phenotype association data of a target human complex disease; wherein the target human complex disease includes at least one human complex disease;

[0008] Performing genome-wide association studies and quantitative trait loci mapping on the genotype-phenotype association data to obtain GWAS data and QTL data;

[0009] Based on a preset window, the GWAS data is screened and grouped to obtain a first leadsnp set; the first leadsnp in each subset of the first leadsnp set is the SNP with the smallest p-value in the GWAS data within the corresponding preset window range; the sizes of the preset windows corresponding to the first leadsnp in different subsets are different; the p-value represents the significance of the degree of genotype-phenotype association;

[0010] Based on the preset window and the first leadsnp set, the QTL data is matched, screened and grouped to obtain a second leadsnp set; the second leadsnp in each subset of the second leadsnp set is the GWAS data and the SNP with the smallest p-value in the QTL data within the corresponding preset window range;

[0011] Based on the second leadsnp set, the GWAS data and the QTL data, co-localization analysis and GWAS-QTL correspondence calculation are performed to determine a target p-value and a target correspondence score;

[0012] Based on the target p-value and the target correspondence score, target leadsNPs are screened from the second leadsNP set to serve as target sites.

[0013] In a second aspect, the present application provides a computer device, comprising: a memory, a processor, and a computer program stored in the memory and executable on the processor, wherein the processor executes the computer program to implement a target screening method for predicting the occurrence of complex human disease phenotypes.

[0014] In a third aspect, the present application provides a computer-readable storage medium having a computer program stored thereon, which, when executed by a processor, implements a target screening method for predicting the occurrence of complex human disease phenotypes.

[0015] According to the specific embodiments provided by the present application, the present application discloses the following technical effects: the present application provides a target screening method, device and medium for predicting the occurrence of complex human disease phenotypes, and performs genome-wide association study and quantitative trait locus mapping on genotype-phenotype association data to obtain GWAS (Genome-Wide Association Study) data and QTL (Quantitative Trait Locus mapping) data; then based on a preset window and based on the p-value, the GWAS data is screened and grouped, and the QTL data is matched, screened and grouped to obtain a second leadsNP set, each leadsNP in this set is the SNP with the smallest p-value in the GWAS data and QTL data within the corresponding preset window range, and the leadsNP in this set are used for co-localization analysis, which can have good co-localization properties. On this basis, co-localization analysis and GWAS-QTL correspondence calculation are performed to determine the target p value and the target correspondence score, that is, co-localization analysis and calculation of the target p value and the target correspondence score are performed on the basis of leadsnp with good co-localization properties, so as to ensure the accuracy of the results. It should be noted that since the leadsnp in the second leadsnp set are obtained after preliminary screening, the number is greatly reduced relative to the GWAS data and QTL data initially obtained, so the efficiency of data processing is improved; and then according to the target p value and the target correspondence score, the target leadsnp is screened from the second leadsnp set as the target target, so that a more accurate target that can predict the occurrence of complex human disease phenotypes can be obtained in a very short time. Based on the target target finally obtained in this application, a large amount of genetic evidence can be excavated in a short time, and the genes and molecular mechanisms of a certain complex human disease can be accurately located, thereby improving high-quality target screening. This application improves the performance, efficiency and accuracy of co-localization screening. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0017] Figure 1 This is an application environment diagram of a target screening method for predicting the occurrence of complex human disease phenotypes in an example of this application;

[0018] Figure 2A schematic diagram of a target screening method for predicting the occurrence of complex human disease phenotypes provided in an example of the present application;

[0019] Figure 3 A schematic diagram of a target screening method for predicting the occurrence of complex human disease phenotypes provided in another example of the present application;

[0020] Figure 4 A schematic diagram of the structure of a computer device provided as an example of the present application. DETAILED DESCRIPTION

[0021] The following will be combined with the drawings in the embodiments of the present application to clearly and completely describe the technical solutions in the embodiments of the present application. Obviously, the described embodiments are only part of the embodiments of the present application, not all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of this application.

[0022] Target prediction and screening based on locus mechanisms provide a new approach to solving the problem of "how to accurately predict the occurrence of these complex disease phenotypes, so that clinicians can timely intervene and prevent the occurrence and development of elderly diseases, which is a difficult problem that urgently needs to be solved." Based on the locus analysis system established in the early stage, further improvements and optimizations can be made to mine massive genetic evidence in a very short time, accurately locate the susceptibility genes and molecular mechanisms in the loci of a certain type of immune cells in peripheral blood, and thus provide high-quality target predictions. At the same time, the perspective of "single cell + parallel mechanism" is introduced to identify a large number of previously ignored "gene-disease / phenotype" regulatory mechanisms. Among them, the new regulatory mechanism will find that the same gene can cause multiple diseases / phenotypes at the same time, thereby discovering new intervention and treatment targets for elderly comorbidities. For example, the rs1801133 variation of the tetrahydrofolate reductase MTHFR gene, which is associated with cancer / coronary heart disease / dementia, has been reported to affect the blood characteristics MCV (mean corpuscular volume), PCT (platelet crit), PLT (platelet count) and RDW-CV (red cell distribution width-coefficient of variation) in CD8 cells by regulating the KIAA2013 gene. In addition, the APOE gene rs7412 (ApoEε2), which is associated with lipid metabolism and many diseases (cardiovascular disease, hypertension, dementia, etc.), affects the reticulocyte count (RET) and the ratio of red blood cells to reticulocytes (RET%) in CD8 cells by regulating lncRNA (CTB-129P6.11) instead of genes related to lipid metabolism. Furthermore, the key regulatory targets can be predicted, the success rate of targeted intervention therapy can be improved, the research and development cycle can be shortened, and the cost can be reduced.

[0023] The research of this application is expected to overturn the traditional target discovery model, and by locating to the single-cell level, accurate prediction and targeted intervention, it will break through the current global problems of late discovery of complex human diseases, co-occurrence of multiple diseases, severe course of disease, and untimely treatment. The traditional target discovery model is step-by-step: first understand the biological mechanism of the target, and then based on the hypothesis, verify the relationship between the target and the disease one by one from "molecule-cell-animal-human"; this application is completely opposite to the locus-oriented target prediction model: without any assumptions in advance, first conduct whole-genome association analysis on real-world populations to discover the statistical relationship between a large number of loci and various diseases; then combine single-cell transcriptomics to locate the truly pathogenic genes and corresponding mechanisms in the loci in a specific type of cell. Therefore, the target recommendation system based on "single cell + parallel mechanism" provided by this application will provide a new research paradigm for the key link of accurate prediction of complex human diseases.

[0024] In order to make the above-mentioned objects, features and advantages of the present application more obvious and easy to understand, the present application is further described in detail below in conjunction with the accompanying drawings and specific implementation methods.

[0025] The target screening method for predicting the occurrence of complex human disease phenotypes provided in the present application can be applied to Figure 1 In the application environment shown. Among them, the terminal 102 communicates with the server 104 through the network. The data storage system can store the data that the server 104 needs to process. The data storage system can be set up separately, or it can be integrated on the server 104, or it can be placed on the cloud or other servers. The terminal 102 can send the genotype-phenotype association data of the target human complex disease to the server 104. After receiving the genotype-phenotype association data of the target human complex disease, the server 104 performs a series of processing and obtains the target target that can be used to predict the occurrence of human complex disease phenotypes. The server 104 can feedback the obtained target target to the terminal 102. In addition, in some embodiments, the target screening method for predicting the occurrence of human complex disease phenotypes can also be implemented separately by the server 104 or the terminal 102.

[0026] The terminal 102 may be, but is not limited to, various desktop computers, laptop computers, etc. The server 104 may be implemented as an independent server or a server cluster consisting of multiple servers, or may be a cloud server.

[0027] like Figure 2 and Figure 3 As shown, a target screening method for predicting the occurrence of complex human disease phenotypes is provided. The method is executed by a computer device, and can be executed by a computer device such as a terminal or a server alone, or by a terminal and a server together. In the embodiment of the present application, the method is applied to Figure 1The server 104 in the example is used for explanation, and the steps include the following steps 201 to 206.

[0028] Step 201, obtaining genotype-phenotype association data of target human complex diseases; wherein the target human complex diseases include at least one human complex disease, which can be set according to actual research needs. In practical applications, relevant data can be directly obtained from a database that has been publicly available on the Internet.

[0029] Step 202, conduct genome-wide association studies and quantitative trait loci positioning on the genotype-phenotype association data to obtain GWAS data and QTL data. In practical applications, some databases that have been made public on the Internet have conducted genome-wide association studies and quantitative trait loci positioning on genotype-phenotype association data, and given the p-value corresponding to each SNP; some databases do not give the p-value corresponding to each SNP, and relevant technicians need to use corresponding technical software or programs to calculate it. Therefore, it is well known in the art and will not be repeated here. Similarly, the r between two adjacent loci in the genome-wide association study can be obtained. 2 value.

[0030] Step 203, based on a preset window, the GWAS data is screened and grouped to obtain a first leadsnp set; the first leadsnp in each subset of the first leadsnp set is the SNP with the smallest p-value in the GWAS data within the corresponding preset window range; the sizes of the preset windows corresponding to the first leadsnp in different subsets are different; the p-value represents the significance of the degree of genotype-phenotype association.

[0031] In an application example, step 203 includes:

[0032] 31) Based on a first preset p-value threshold, the GWAS data is screened; in one example, the first preset p-value threshold is set to 5e-08 (i.e., 5×10 -8 ), then the data with p value <5e-08 in GWAS data will be screened out.

[0033] 32) Based on multiple presets 2 The GWAS data after screening are grouped to obtain multiple SNP groups to be processed; wherein, r 2 The value represents the degree of association between alleles at the loci; in one example, a preset r 2 The threshold is 0.2, then according to r 2 The linkage disequilibrium in the GWAS data after screening was removed by the standard of >0.2, and then the data were grouped.

[0034] 33) For any of the SNP groups to be processed, determine the SNP with the smallest p value from the SNP group to be processed and use it as the benchmark SNP. In an example algorithm, the benchmark SNP can be defined as the lead SNP. eLD .

[0035] 34) Obtain preset windows of different sizes; in one example, the sizes of the preset windows are 10K, 30K, 50K, 100K, etc., and the sizes and quantities of the preset windows can be adjusted by relevant technical personnel.

[0036] 35) For a preset window of any size, starting from the position of the benchmark SNP, the window is expanded in two directions respectively. When the benchmark SNP is the SNP with the smallest p value within the range of the preset window, the benchmark SNP is marked as the first leadsNP corresponding to the preset window.

[0037] 36) Based on the size of the preset window, group all the first leadsnp to obtain a plurality of first leadsnp subsets; each of the first leadsnp subsets corresponds to a preset window of a certain size; and a plurality of the first leadsnp subsets constitute a first leadsnp set. In other words, in this application, a certain window is defined as needed, and for leadsnp eLD , we need to consider whether it appears as a lead under a certain window, and divide it into different groups based on this. For example, the set of leadsnp that appear as a lead under 100K is recorded as the first leadsnp subset corresponding to 100K. In order to facilitate subsequent mathematical derivation, it can be expressed as leadsnps gwas 100K .

[0038] For ease of understanding, an example is given below. This example is only for illustration and to assist understanding: Assume that there are 100 SNPs in the GWAS data. 2 After the values ​​are grouped, ten SNP groups are obtained, and one SNP group has one lead SNP. eLD ; If the current window is 100K, then leadsnp eLD As a starting point, expand 50K in each direction, and then determine the leadsnp within the combined range of 100K eLD Is it still the smallest p value? If so, then the leadsnp eLDMarked as the first leadsnp corresponding to 100K. Similarly, judgments can be made under windows of 200K, 300K, etc. When the ten SNP groups to be processed have completed the judgment of whether they are leads under 100K, 200K, and 300K, all SNPs that are leads under 100K are formed into a subset, and similarly, subsets corresponding to 200K and 300K are obtained. Finally, multiple subsets constitute the first leadsnp set.

[0039] Specifically, there are ten lead SNPs corresponding to ten SNPs in the ten SNP groups to be processed. eLD , if they are marked as snp1, snp2, ..., snp9, snp10, and the p-value of snp4 is less than the p-value of snp2; and if snp2, snp4, and snp8 are still the lead in 100K, then the first lead snp set corresponding to 100K includes snp2, snp4, and snp8. As for the p-value of snp4 being less than the p-value of snp2, but snp2 and snp4 are still retained as the first lead snp, it is because the pos difference between snp2 and snp4 may be 200K, but the current window is 100K, and snp4 is not within the window range starting with snp2, so snp2 is the snp with the smallest p-value within the 100K range, so it is marked as the first lead snp.

[0040] The above step 203 can screen out the lead SNPs in the GWAS data. The lead SNPs under a certain window refer to the SNPs with the smallest p-value among all the SNPs in this window, that is, the most significant SNPs.

[0041] Step 204, based on the preset window and the first leadsnp set, the QTL data is matched and screened to obtain a second leadsnp set; the second leadsnp in each subset of the second leadsnp set is the SNP with the smallest p-value in the GWAS data and the QTL data within the corresponding preset window range.

[0042] In one application example, step 204 includes:

[0043] 41) Based on a second preset p-value threshold, the QTL data is screened; in one example, the second preset p-value threshold is set to 0.05, and the data with a p-value < 0.05 in the QTL data is screened out. The second preset p-value threshold is not limited to 0.05, and relevant technicians can adjust it as needed.

[0044] 42) Based on the first leadsnp set, the QTL data after screening is matched to obtain significant SNP sites corresponding to different gene types in the QTL data. Specifically, the leadsnp in the GWAS data obtained by step 203 is matched with the SNP in the QTL data obtained by step 41). In this process, the gene type appearing in the QTL data is recorded as gene qtl , where the i-th gene is denoted as gene i , and then divide the obtained results into different gene types, recorded as

[0045] 43) For each gene type, starting from the corresponding significant SNP site in the QTL data, expansion is performed in two directions respectively. When the significant SNP site is the SNP with the smallest p-value within the range of a preset window of any size, the significant SNP site is marked as the second leadsNP corresponding to the preset window; multiple second leadsNPs of the same size as the corresponding preset window constitute a second leadsNP subset; multiple second leadsNP subsets constitute a second leadsNP set.

[0046] The size of the preset window used in this step corresponds to the size of the preset window used in step 203, that is, in this step, based on the preset window, the size of the preset window obtained in step 42) is Consider whether a lead is present under a certain window and divide it into different groups. For example, the set of leadsnp that presents a lead under 100K is recorded as The set obtained in this step is different from the set obtained in step 35). The leadsnp in the former is the most significant in the GWAS data and the most significant in the QTL data, while the leadsnp in the latter is the most significant only in the GWAS data.

[0047] For simplicity, the second leadsnp set is recorded as φ n ,φ n is a set of n leadsNPs. In another application example, the SNPs corresponding to the leadsNPs in the QTL data under each window are sorted by p value at the same time, and the sorting is recorded as sortφ n MK , where M is the value of the window. For example, when the window is 100K, the sort is sortφ n 100KIt should be noted that the order set in this step is the basis for the order of co-localization analysis in the subsequent steps. By setting the order in advance, the subsequent co-localization analysis can be ensured to be carried out stably and quickly.

[0048] Since the leadsNPs in the QTL data and the leadsNPs in the GWAS data are not necessarily the same site, that is, a site is the most significant in the GWAS data, but not necessarily the most significant in the QTL data, therefore, the above step 204 is set, and after processing the GWAS data, it is also necessary to determine whether it is also the leadsNP (i.e., the most significant) in the QTL data.

[0049] Step 205, based on the second leadsnp set, the GWAS data and the QTL data, perform co-localization analysis and GWAS-QTL correspondence calculation to determine a target p value and a target correspondence score.

[0050] In an application example, step 205 includes:

[0051] 51) extracting a test leadsnp set from the second leadsnp set; the test leadsnp set includes a plurality of test leadsnp subsets, each of which includes a plurality of leadsnp. For example, in one example, 1% of the second leadsnp set is randomly selected as a test set, which is divided into three subsets, each of which contains one thousand leadsnp, and all three leadsnp subsets are subjected to co-localization analysis, and the results obtained from the co-localization analysis are sorted according to the p-value and different correspondence scores are selected for measurement, and the specific steps are shown as follows.

[0052] 52) performing co-localization analysis on each of the test leadsnp subsets to obtain a co-localization analysis result; the co-localization analysis result includes a test p value corresponding to each leadsnp in the test leadsnp subset.

[0053] 53) Calculating a target p-value based on the co-localization analysis results corresponding to the plurality of test leadsNP subsets.

[0054] In a specific practical application, step 53) includes:

[0055] 531) For the co-localization analysis results corresponding to any of the test leadsnp subsets, multiple leadsnp sites with good co-localization properties are determined from all leadsnp in the test leadsnp subset according to the third preset p-value threshold; that is, leadsnp with p-values ​​less than the third preset p-value threshold are regarded as leadsnp sites with good co-localization properties. Corresponding to the three test leadsnp subsets mentioned above, the numbers of leadsnp sites with good co-localization properties obtained are 20, 22, and 21, respectively.

[0056] 532) Determine the site with the largest test p-value from the multiple leadsNP sites with good co-localization properties; specifically, since the smaller the p-value, the better the co-localization property, the points with the largest p-values ​​from the multiple leadsNP sites with good co-localization properties in the three subsets are respectively selected, and the corresponding p-values ​​can be marked as P1, P2, and P3.

[0058] 533) Based on the sites with the largest test p-values ​​corresponding to the multiple test leadsnp subsets, the mean of the test p-values ​​is calculated to obtain the target p-value, and the calculation formula is:

[0059]

[0060] The target p value is an effective threshold boundary. The p value greater than the target p value has only a small probability of having good co-localization properties.

[0061] 54) For each of the test leadsnp subsets, combining the GWAS data and the QTL data, calculating the GWAS-QTL correspondence of each of the leadsnp.

[0062] In a specific practical application, step 54) includes:

[0063] 541) For any leadsnp in the test leadsnp subset, the GWAS data and the QTL data are cut according to the corresponding preset windows to obtain the SNPs group corresponding to the leadsnp; the SNPs group includes the site corresponding to each SNP, the p value in the GWAS data and the p value in the QTL data.

[0064] Further specifically, based on any leadsnp in the test leadsnp subset (which can be represented as leadsnp i, i∈n, i.e., the specific i-th leadsnp in the leadsnp set), the GWAS data and the QTL data are cut according to the corresponding window according to pos (the position of leadsnp), so as to obtain the set of all SNPs corresponding to the leadsnp in a certain window, i.e., the SNPs group, which can be expressed by the following formula:

[0065]

[0066] Among them, the number of SNPs in the SNPs group is Nsnps i,j ; Any snp∈snps in the snps group i,j , which can be recorded as x i,j,k , Consider the collection of windows For a specific The corresponding leadsnp is recorded as Represents the j-th window in the window set.

[0067] 542) For any SNP in the SNPs group, the p-value in the GWAS data and the p-value in the QTL data corresponding to the SNP are normalized respectively, and then the GWAS-QTL correspondence of the lead SNP is calculated using the following formula:

[0068]

[0069] Among them, θ i,j is the GWAS-QTL correspondence of the leadsnp, and the corresponding θ 1,1 It indicates the GWAS-QTL correspondence of the first leadsnp in the set when the window is 100K; and They are the p-values ​​in the GWAS data and the p-values ​​in the QTL data corresponding to the normalized SNPs (-log10); is the indicative function, is a set of weight factors: [] is the Gaussian rounding function; Nsnps i,j is the number of SNPs in the SNPs group; and They are the p-values ​​in the GWAS data and the p-values ​​in the QTL data corresponding to the SNPs (-log10); and They are the sites in the GWAS data and the sites in the QTL data corresponding to the SNPs, respectively.

[0070] The GWAS-QTL correspondence is a value greater than 0. The higher the value, the better the co-localization property of the leadsnp. In subsequent comparisons, it needs to be combined with the p-value sorting to obtain the highest accuracy. Both are indispensable. That is to say, this application sets two thresholds, one is the p-value threshold (i.e., the target p-value), and the other is the correspondence score threshold (i.e., the target correspondence score). Only leadsnp that meet the requirements will be retained, and others will be eliminated.

[0071] 55) determining a target correspondence score according to the GWAS-QTL correspondence and co-localization analysis results of each of the leadsnp in the plurality of test leadsnp subsets.

[0072] In a specific practical application, step 55) includes:

[0073] 551) For any of the test leadsnp subsets, a plurality of preset correspondence scores with equal intervals are obtained. For example, the equal interval is set to 5, and based on this, a plurality of preset correspondence scores are set to 30, 35, and 40 respectively.

[0074] 552) For any of the preset correspondence scores, based on the GWAS-QTL correspondence of each of the leadsnp in the test leadsnp subset, multiple leadsnp sites whose GWAS-QTL correspondence is less than the preset correspondence score are screened from the test leadsnp subset.

[0075] Taking the preset correspondence score of 30 as an example, multiple lead SNPs with GWAS-QTL correspondence less than 30 can be obtained through step 552).

[0076] 553) Based on the co-localization analysis results, multiple lead snp sites whose GWAS-QTL correspondences are less than the preset correspondence scores are screened again, and the lead snp sites with good co-localization properties are retained, and the proportion of retained sites is calculated.

[0077] Corresponding to the multiple leadsNPs with a GWAS-QTL correspondence less than 30 obtained in the previous step, according to the co-localization analysis results corresponding to each leadsNP, when its p-value is less than the third preset p-value threshold, it is characterized as a leadsNP site with good co-localization properties; retain all leadsNP sites with good co-localization properties, and calculate their proportion in all leadsNPs with a GWAS-QTL correspondence less than 30. For example, the number of leadsNPs with a GWAS-QTL correspondence less than 30 obtained in the previous step is 30, of which there are 15 leadsNP sites with good co-localization properties, then the corresponding proportion of retained sites is 50%.

[0078] Similarly, we can obtain the proportion of retained sites when the preset correspondence scores are 35 and 40 respectively.

[0079] 554) Based on the ratios of retained sites corresponding to multiple preset correspondence scores, the preset correspondence score corresponding to the largest ratio of retained sites is selected and marked as the stand-by correspondence score; that is, the largest ratio of retained sites is selected from the ratios of retained sites corresponding to preset correspondence scores of 30, 35, and 40, and the preset correspondence score corresponding to the ratio, such as 35, is used as the stand-by correspondence score for subsequent processing.

[0080] 555) Based on the standby correspondence scores corresponding to the multiple test leadsnp subsets, average calculation is performed to obtain a target correspondence score.

[0081] The above step 205 obtains the key maximum p-value and minimum correspondence score in advance based on a test set randomly selected from the data set, and then uses these two parameters to screen the total leadsnp data set, namely the following step 206.

[0082] Step 206, based on the target p-value and the target correspondence score, select target leadsnp from the second leadsnp set to serve as target targets. Specifically, based on the target p-value and the target correspondence score, when selecting target leadsnp from the second leadsnp set, The conditional leadsnp is used as the target leadsnp; where maxP is the target p-value and minscore is the target correspondence score. is the p-value of the leadsnp in the second leadsnp set, is the GWAS-QTL correspondence of the leadsnp in the second leadsnp set.

[0083] The co-localization analysis mentioned in the article is such an analysis method: when studying the relationship between a certain SNP and a trait, we hope to obtain such a judgment: the SNP affects the trait by regulating the expression of a certain gene. Specifically, there are four scenarios for co-localization analysis:

[0084] H0: Phenotype 1 (GWAS) and phenotype 2 (QTL, such as eQTL) are not significantly associated with all SNP sites in a certain genomic region.

[0085] H1 / H2: Phenotype 1 (GWAS) or phenotype 2 (QTL, such as eQTL) is significantly associated with the SNP locus in a certain genomic region.

[0086] H3: Phenotype 1 (GWAS) and phenotype 2 (QTL, such as eQTL) are significantly associated with SNPs in a certain genomic region but are driven by different causal variants.

[0087] H4: Phenotype 1 (GWAS) and phenotype 2 (QTL, such as eQTL) are significantly associated with SNP sites in a certain genomic region and are driven by the same causal variant site.

[0088] By using the co-localization method based on Bayesian inference, considering GWAS data and QTL data, and then observing the obtained PP.H4.abf value, when this value is greater than 0.7, the site is considered to be "co-localized", that is, it has good co-localization properties. From a statistical point of view, this value means how likely it is that the SNP affects the trait by regulating the expression level of the gene (eQTL is an example).

[0089] Compared with the prior art, the target targets screened by this application have better co-localization screening effects, and improve the performance, efficiency and accuracy of co-localization screening. In a specific test, the data processing steps of steps 201-204 of this application are sufficient to support rapid results, and the performance has been greatly improved; on this basis, the parameter analysis and data screening of steps 205-206 further improve the performance and accuracy. From the perspective of accuracy, this application combines p-value sorting and correspondence to select 200 leadsNPs, of which there are a total of 112 sites with good co-localization properties. Compared with the prior art, the accuracy can be increased from 1.47% to 56%. From the perspective of performance, in the test leadsnp set of this application, among the 13,599 leadsnp, a total of 193 leadsnp sites with good co-localization properties are included. Using maxP as the threshold for screening, 3,000 leadsnp with smaller p values ​​are obtained. This part of the leadsnp covers 191 of the above 193 leadsnp sites with good co-localization properties. From this perspective, the method of this application can eliminate nearly 80% of the leadsnp, which cannot obtain good co-localization results. By this method, a huge improvement in performance can be achieved.

[0090] Finally, it is emphasized once again that the reason why this application can achieve good performance and greatly improve accuracy is that the corresponding improvement steps are as follows:

[0091] Step 201-Step 204: A new data processing architecture is proposed. This architecture method can quickly screen leadsNPs and use them for co-localization analysis, and has good co-localization properties. In a certain verification experiment, 29 blood characteristic phenotypes, 5 autoimmune disease phenotypes, and eight cell types were analyzed using the method of this application. There are a total of 1281221061 SNP sites in the GWAS data and 345972761 SNP sites in the evQTL data. The new architecture method provided by this application can perform a co-localization analysis on all data within 48 hours.

[0092] Step 205-Step 206: A new judgment parameter is proposed: target p value and target correspondence score. Combining these two to screen leadsnp greatly improves the accuracy and performance of co-localization. On the basis of steps 201-204, by eliminating leadsnp, the performance of cutting data and co-localization can be greatly improved. The time used for cutting data for co-localization is optimized from 24 hours to 6 hours, and the overall running time is further optimized to co-localize valuable data within 30 hours. Analysis. At the same time, in the test data set, by obtaining the key parameter correspondence score and P value sorting, a total of 112 sites among the 200 selected sites have good co-localization properties. The accuracy rate has increased from 193 sites with good co-localization properties in the original 13599 sites, with a proportion of about 1.47%, to 56%, achieving a significant improvement in accuracy and a significant optimization of overall performance.

[0093] In an exemplary embodiment, a computer device is provided. The computer device may be a server or a terminal. The internal structure diagram thereof may be as follows: Figure 4 As shown. The computer device includes a processor, a memory, an input / output interface (Input / Output, referred to as I / O) and a communication interface. Among them, the processor, the memory and the input / output interface are connected through a system bus, and the communication interface is connected to the system bus through the input / output interface. Among them, the processor of the computer device is used to provide computing and control capabilities. The memory of the computer device includes a non-volatile storage medium and an internal memory. The non-volatile storage medium stores an operating system, a computer program and a database. The internal memory provides an environment for the operation of the operating system and the computer program in the non-volatile storage medium. The input / output interface of the computer device is used to exchange information between the processor and an external device. The communication interface of the computer device is used to communicate with an external terminal through a network connection. When the computer program is executed by the processor, a target screening method for predicting the occurrence of complex human disease phenotypes is implemented.

[0094] In an exemplary embodiment, a computer-readable storage medium is provided, storing a computer program, and when the computer program is executed by a processor, the steps in the above method embodiments are implemented.

[0095] It should be noted that the user information (including but not limited to user device information, user personal information, etc.) and data (including but not limited to data used for analysis, stored data, displayed data, etc.) involved in this application are all information and data authorized by the user or fully authorized by all parties, and the collection, use and processing of relevant data must comply with relevant regulations.

[0096] Those of ordinary skill in the art can understand that all or part of the processes in the above-mentioned embodiment methods can be completed by instructing the relevant hardware through a computer program, and the computer program can be stored in a non-volatile computer-readable storage medium. When the computer program is executed, it can include the processes of the embodiments of the above-mentioned methods. Among them, any reference to the memory, database or other medium used in the embodiments provided in the present application can include at least one of non-volatile and volatile memory. Non-volatile memory can include read-only memory (ROM), magnetic tape, floppy disk, flash memory, optical memory, high-density embedded non-volatile memory, resistive random access memory (ReRAM), magnetic random access memory (MRAM), ferroelectric random access memory (FRAM), phase change memory (PCM), graphene memory, etc. Volatile memory can include random access memory (RAM) or external cache memory, etc. By way of illustration and not limitation, RAM may be in various forms, such as static random access memory (SRAM) or dynamic random access memory (DRAM).

[0097] The database involved in each embodiment provided in this application may include at least one of a relational database and a non-relational database. The non-relational database may include a distributed database based on blockchain, etc., but is not limited thereto. The processor involved in each embodiment provided in this application may be a general-purpose processor, a central processing unit, a graphics processor, a digital signal processor, a programmable logic device, a data processing logic device based on quantum computing, etc., but is not limited thereto.

[0098] The technical features of the above embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0099] This article uses specific examples to illustrate the principles and implementation methods of this application. The description of the above embodiments is only used to help understand the method and core ideas of this application. At the same time, for those skilled in the art, according to the ideas of this application, there will be changes in the specific implementation methods and application scope. In summary, the content of this specification should not be understood as limiting this application.

Claims

1. A target screening method for predicting the occurrence of complex human disease phenotypes, It is characterized in that The target screening method for predicting the occurrence of complex human disease phenotypes comprises: Acquire genotype-phenotype association data of a target human complex disease; wherein the target human complex disease includes at least one human complex disease; Performing genome-wide association studies and quantitative trait loci mapping on the genotype-phenotype association data to obtain GWAS data and QTL data; Based on a preset window, the GWAS data is screened and grouped to obtain a first leadsnp set; the first leadsnp in each subset of the first leadsnp set is the SNP with the smallest p-value in the GWAS data within the corresponding preset window range; the sizes of the preset windows corresponding to the first leadsnp in different subsets are different; the p-value represents the significance of the degree of genotype-phenotype association; Based on the preset window and the first leadsnp set, the QTL data is matched, screened and grouped to obtain a second leadsnp set; the second leadsnp in each subset of the second leadsnp set is the GWAS data and the SNP with the smallest p-value in the QTL data within the corresponding preset window range; Based on the second leadsnp set, the GWAS data and the QTL data, co-localization analysis and GWAS-QTL correspondence calculation are performed to determine a target p-value and a target correspondence score; Based on the target p-value and the target correspondence score, target leadsNPs are screened from the second leadsNP set to serve as target sites.

2. The target screening method for predicting the occurrence of complex human disease phenotypes according to claim 1, It is characterized in that Based on a preset window, the GWAS data is screened to obtain a first leadsnp set, including: Based on a first preset p-value threshold, screening the GWAS data; Based on multiple presets 2 The GWAS data after screening are grouped to obtain multiple SNP groups to be processed; wherein, r 2 The value represents the degree of association between alleles at the loci; For any of the SNP groups to be processed, determine the SNP with the smallest p-value from the SNP group to be processed and use it as the benchmark SNP; Get preset windows of different sizes; For a preset window of any size, starting from the position of the reference SNP, the window is expanded in two directions respectively. When the reference SNP is the SNP with the smallest p value within the range of the preset window, the reference SNP is marked as the first lead SNP corresponding to the preset window; Based on the size of the preset window, all the first leadsnp are grouped to obtain a plurality of first leadsnp subsets; each of the first leadsnp subsets corresponds to a preset window of a size; and a plurality of the first leadsnp subsets constitute a first leadsnp set.

3. The target screening method for predicting the occurrence of complex human disease phenotypes according to claim 1, It is characterized in that Based on the preset window and the first leadsnp set, matching and screening the QTL data to obtain a second leadsnp set includes: Based on a second preset p-value threshold, screening the QTL data; Based on the first leadsnp set, matching the screened QTL data to obtain significant SNP sites corresponding to different gene types in the QTL data; For each gene type, starting from the corresponding significant SNP site in the QTL data, expansion is performed in two directions respectively. When the significant SNP site is the SNP with the smallest p-value within the range of a preset window of any size, the significant SNP site is marked as the second leadsNP corresponding to the preset window; multiple second leadsNPs of the same size in the corresponding preset window constitute a second leadsNP subset; multiple second leadsNP subsets constitute a second leadsNP set.

4. The target screening method for predicting the occurrence of complex human disease phenotypes according to claim 1, It is characterized in that Based on the second leadsnp set, the GWAS data and the QTL data, co-localization analysis and GWAS-QTL correspondence calculation are performed to determine a target p value and a target correspondence score, including: Extracting a test leadsnp set from the second leadsnp set; the test leadsnp set includes a plurality of test leadsnp subsets, each of the test leadsnp subsets includes a plurality of leadsnp; For each of the test leadsnp subsets, a colocalization analysis is performed to obtain a colocalization analysis result; the colocalization analysis result includes a test p value corresponding to each leadsnp in the test leadsnp subset; Calculating a target p-value based on the co-localization analysis results corresponding to the plurality of test leadsNP subsets; For each of the test leadsnp subsets, combining the GWAS data and the QTL data, calculating the GWAS-QTL correspondence of each of the leadsnp; A target correspondence score is determined based on the GWAS-QTL correspondence and co-localization analysis results of each of the leadsnp subsets tested.

5. The target screening method for predicting the occurrence of complex human disease phenotypes according to claim 4, It is characterized in that For each of the test leadsnp subsets, combining the GWAS data and the QTL data, calculating the GWAS-QTL correspondence of each of the leadsnp, including: For any leadsnp in the test leadsnp subset, the GWAS data and the QTL data are cut according to the corresponding preset windows to obtain a SNPs group corresponding to the leadsnp; the SNPs group includes the site corresponding to each SNP, the p value in the GWAS data and the p value in the QTL data; For any SNP in the SNPs group, the p-value in the GWAS data and the p-value in the QTL data corresponding to the SNP are normalized respectively, and then the GWAS-QTL correspondence of the lead SNP is calculated using the following formula: Among them, θ i,j is the GWAS-QTL correspondence of the leadsnp; and They are the p-values ​​in the GWAS data and the p-values ​​in the QTL data corresponding to the normalized SNPs; is the indicator function, λ r2 is a set of weight factors: [] is the Gaussian rounding function; Nsnps i,j is the number of SNPs in the SNPs group; and are the p-values ​​in the GWAS data and QTL data corresponding to the SNPs, respectively; and They are the sites in the GWAS data and the sites in the QTL data corresponding to the SNPs, respectively.

6. The target screening method for predicting the occurrence of complex human disease phenotypes according to claim 4, It is characterized in that Determining a target correspondence score according to the GWAS-QTL correspondence and co-localization analysis results of each of the leadsnp subsets in the plurality of test leadsnp subsets comprises: For any of the test leadsnp subsets, obtaining a plurality of preset correspondence scores at equal intervals; For any of the preset correspondence scores, based on the GWAS-QTL correspondence of each of the leadsnp in the test leadsnp subset, a plurality of leadsnp sites having a GWAS-QTL correspondence less than the preset correspondence score are screened from the test leadsnp subset; Based on the co-localization analysis results, multiple lead sNP sites whose GWAS-QTL correspondences are less than the preset correspondence scores are screened again, and lead sNP sites with good co-localization properties are retained, and the proportion of retained sites is calculated; Based on the proportions of the reserved sites corresponding to the plurality of preset correspondence scores, selecting the preset correspondence score corresponding to the largest proportion of the reserved sites and marking it as the correspondence score to be used; Based on the standby correspondence scores corresponding to the plurality of test leadsnp subsets, a mean calculation is performed to obtain a target correspondence score.

7. The target screening method for predicting the occurrence of complex human disease phenotypes according to claim 4, It is characterized in that Calculating a target p-value based on the co-localization analysis results corresponding to the plurality of test leadsNP subsets, including: For the co-localization analysis results corresponding to any of the test leadsnp subsets, determining a plurality of leadsnp sites with good co-localization properties from all the leadsnp in the test leadsnp subset according to a third preset p-value threshold; Determine a site with the largest test p value from a plurality of lead sNP sites with good co-localization properties; Based on the sites with the largest test p-values ​​corresponding to the multiple test leadsnp subsets, the mean of the test p-values ​​is calculated to obtain the target p-value.

8. The target screening method for predicting the occurrence of complex human disease phenotypes according to claim 1, It is characterized in that Based on the target p-value and the target correspondence score, when selecting the target leadsnp from the second leadsnp set, the leadsnp that satisfies The conditional leadsnp is used as the target leadsnp; Among them, maxP is the target p value, minscore is the target correspondence score, is the p-value of the leadsnp in the second leadsnp set, is the GWAS-QTL correspondence score of the leadsnp in the second leadsnp set.

9. A computer device, include: A memory, a processor, and a computer program stored in the memory and executable on the processor, wherein the processor executes the computer program to implement the target screening method for predicting the occurrence of complex human disease phenotypes as described in any one of claims 1 to 8.

10. A computer-readable storage medium having a computer program stored thereon, It is characterized in that When the computer program is executed by a processor, the target screening method for predicting the occurrence of complex human disease phenotypes described in any one of claims 1 to 8 is implemented.